Eli Lilly and Company (NYSE:LLY) Declares Quarterly Dividend of $1.73

Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend on Monday, June 22nd. Investors of record on Friday, August 14th will be paid a dividend of 1.73 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th.

Eli Lilly and Company has raised its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a dividend payout ratio of 23.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Eli Lilly and Company to earn $44.60 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 15.5%.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,103.69 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.04 trillion, a PE ratio of 39.21, a price-to-earnings-growth ratio of 1.20 and a beta of 0.53. The business’s fifty day moving average price is $1,019.04 and its 200 day moving average price is $1,017.54.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed a research and collaboration agreement with BioArctic to combine Lilly’s drug candidate with BioArctic’s BrainTransporter technology, adding another neuroscience shot on goal and strengthening Lilly’s pipeline. BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology
• Positive Sentiment: Analysts and market commentary remain constructive on Lilly’s weight-loss business, with coverage pointing to surging sales and the company’s strong position in the expanding GLP-1/anti-obesity market. Cantor Fitzgerald Pounds the Table on Eli Lilly Stock (LLY) Heading into Q2 Earnings Season
• Positive Sentiment: Lilly’s board declared a third-quarter dividend of $1.73 per share, reinforcing its strong cash generation and shareholder returns. Lilly declares third-quarter 2026 dividend
• Neutral Sentiment: Berenberg raised its price target on LLY to $1,135 from $1,050 but kept a Hold rating, suggesting limited immediate upside from current levels. Berenberg adjusts price target on Eli Lilly to $1,135 from $1,050, maintains hold rating
• Negative Sentiment: Separate headlines about hospitals criticizing Lilly’s 340B policy move could keep some political and regulatory pressure on the stock. Hospitals irate after Eli Lilly follows through on 340B ultimatum

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.